INFO & CONTACTS:  +39 02 2390 1

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Phase: Phase III clinical trials

Principal Investigator: Dott.ssa Angi Martina

Main Facility: Struttura Complessa Chirurgia Generale 4 – Chirurgia del Melanoma e dei Tumori Oculari

Drug: Darovasertib

Pathologies: Melanoma

The drug darovasertib will be evaluated in the neoadjuvant setting in patients with primary, non-metastatic uveal melanoma (UM) requiring plaque brachytherapy (PB) or enucleation. For the patient population eligible for PB (Cohort 1), it is hypothesized that, compared to immediate PB, darovasertib reduces tumor size and the radiation dose delivered via PB. For the patient population eligible for enucleation (Cohort 2), it is hypothesized that the drug reduces tumor size, thereby decreasing the need for enucleation as the primary treatment.

Last update: 06/10/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe